Many studies have shown that the immune efficacy of ALT-803 in normal animals is similar to that in tumor animal models, suggesting that ALT-803 suppresses cancer development by enhancing the activity of CD8+ T and NK cells and the expression of MCP-1 and GzB (Figure 1). The gene discussed is CD8A; the disease is neoplasm.